Eli Lilly has been in recent news for various reasons. Notably, they have no affiliation with
Hims & Hers, however, their weight-loss drug will be sold on its platform. More significantly, their drug lepodisiran
reduced genetically inherited heart disease risk by 94% at its highest tested dose, which has stirred considerable interest. Despite recent market malaise and trade tension uncertainties, positive endorsements have emerged like Jim Cramer advising investors to 'Stay Long' on Eli Lilly. Other trending stories include implications of Medicare excluding weight-loss drugs causing Novo stocks to dive, expansion of the LillyDirect platform to improve access to Alzheimer's disease care and Eli Lilly confronting pharmacies producing unauthentic versions of Zepbound. Their gene-editing biomedical offering has been recognized as highly attractive. Sangamo’s license deal with Eli Lilly has generated positive investor attention too. The company has reported its
full Q4 2024 financial results along with 2025 guidance, following a minor setback with a rare revenue miss in Q3. Their dividend payment has been identified as favorable by several. Major biotech players like Novo Nordisk and Eli Lilly are moving towards heart health research.
Eli Lilly LLY News Analytics from Tue, 07 Jan 2025 08:00:00 GMT to Sat, 05 Apr 2025 12:31:07 GMT -
Rating 6
- Innovation 7
- Information 8
- Rumor 4
